Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S.
FDA OKs Ketamine For Treating Organ Transplant Injuries With ‘Orphan Drug’ Status
The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu
NGOs Raise Money To Help Stem Opioid Addiction With Psychedelics Program
The 100 Million Ways Foundation (100MW), a not-for-profit organization focused on harm reduction and improving quality of life of those with opioid use disorders, pulled in nearly $100,000 in fundraising at a recent gala commemorating the work carried out so far.
Irwin Naturals: A New Acquisition And The Building Of A National Ketamine-Clinics Chain
The popular herbal supplement producer Irwin Naturals Inc. (OTC: IWINF) has acquired two additional ketamine clinics through the purchase of Invictus Clinics LLC’s assets.